Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as an injectable formulation for intracisternal or intravenous use. It is used for prevention and treatment of cerebral vasospasm following subarachnoid hemorrhage in adults. GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Nimotop acts on the cerebral vasculature to prevent and treat vasospasm after subarachnoid hemorrhage. - Subarachnoid hemorrhage (aneurysmal): reduces incidence and severity of cerebral vasospasm, improving neurological outcome. - Delayed cerebral ischemia: helps maintain cerebral perfusion and lowers risk of ischemic deficits. - Neuroprotection after brain injury: supports neuronal survival by enhancing blood flow to vulnerable brain regions.

Adverse reactions may occur with Nimotop use.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient blood‑pressure drop. - Nausea: occasional gastrointestinal upset. - Flushing: warmth and redness of skin. - Dizziness: sensation of light‑headedness. - Bradycardia: slower than normal heart rate.

Serious or Rare Side Effects: - Severe hypotension: may require medical intervention. - Myocardial infarction: rare cardiac event. - Allergic reactions: rash, itching, or anaphylaxis. - Liver enzyme elevation: abnormal hepatic function tests. - Seizures: infrequent neurologic episodes.

Before initiating therapy, consider the following precautions. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution; liver function should be assessed. - Hypotension: observe blood pressure closely during administration. - Concomitant vasodilators: risk of additive blood‑pressure lowering effects. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Nimotop may interact with several medications.

Major Interactions (Avoid): - Other calcium channel blockers: risk of profound hypotension. - Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase plasma nimodipine levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Beta‑blockers: additive bradycardia. - Nitrates: enhanced vasodilatory response. - Diuretics: may potentiate hypotensive episodes.